Who are ARGX-113 with rHuPH20's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vyvgart, UPLIZNA, RYSTIGGO, Blenrep, rFVIIIFc, Efgartigimod PH20 SC.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/argx-113-with-rhuph20.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

ARGX-113 with rHuPH20 — Competitive Intelligence Brief

ARGX-113 with rHuPH20 (ARGX-113 with rHuPH20) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody. Area: Immunology.

phase 1 Monoclonal antibody FcRn Immunology Biologic Live · refreshed every 30 min

Target snapshot

ARGX-113 with rHuPH20 (ARGX-113 with rHuPH20) — argenx. Monoclonal antibody targeting the neonatal Fc receptor (FcRn)

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ARGX-113 with rHuPH20 TARGET	ARGX-113 with rHuPH20	argenx	phase 1	Monoclonal antibody	FcRn
Vyvgart	EFGARTIGIMOD ALFA	Argenx Bv	marketed	Endoglycosidase [EPC]	IgG receptor FcRn large subunit p51	2021-01-01
UPLIZNA	UPLIZNA	Amgen	marketed	FcRn antagonist	FcRn (neonatal Fc receptor)
RYSTIGGO	ROZANOLIXIZUMAB-NOLI	UCB INC	marketed	Neonatal Fc Receptor Blocker [EPC]	IgG receptor FcRn large subunit p51
Blenrep	Blenrep	Duke University	marketed		Low affinity immunoglobulin gamma Fc region receptor III-A, High affinity immunoglobulin gamma Fc receptor I, IgG receptor FcRn large subunit p51
rFVIIIFc	rFVIIIFc	Bioverativ Therapeutics Inc.	marketed	Recombinant clotting factor (Factor VIII replacement therapy)	Factor VIII / FcRn (neonatal Fc receptor)
Efgartigimod PH20 SC	Efgartigimod PH20 SC	argenx	marketed	FcRn antagonist	Neonatal Fc receptor (FcRn)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody class)

Pfizer · 7 drugs in this class
argenx · 7 drugs in this class
Johnson & Johnson · 2 drugs in this class
German CLL Study Group · 2 drugs in this class
Amgen · 2 drugs in this class
Hoffmann-La Roche · 2 drugs in this class
Brii Biosciences Limited · 2 drugs in this class
Alexion Pharmaceuticals, Inc. · 2 drugs in this class
Biotest · 2 drugs in this class
Fondazione Italiana Linfomi - ETS · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ARGX-113 with rHuPH20 — Competitive Intelligence Brief. https://druglandscape.com/ci/argx-113-with-rhuph20. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab